Comparative Study of the Combination of Trastuzumab with Conventional Radiotherapy versus Trastuzumab with Hypofractionated Radiotherapy in HER2/neu Positive Breast Cancer | ||||
| SECI Oncology Journal | ||||
| Volume 13, Issue 3, July 2025, Page 179-185 PDF (325.33 K) | ||||
| DOI: 10.21608/secioj.2025.441223 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: Despite the frequent combination of trastuzumab and irradiation in breast cancer treatment, there is little evidence about the safety of their concurrent adjuvant administration, particularly with hypo fractionated radiation therapy (Hypo-RT). We conducted this study to examine the safety of concurrent administration of Trastuzumab with conventional radiation (Conv- RT) compared to Trastuzumab with Hypo-RT in Her2/neu breast cancer, focusing on cardiac and cutaneous toxicities. Methodology: This prospective randomized open-label study included 150 patients with localized breast cancer who were referred to the medical and radiation oncology departments at South Egypt Cancer Institute, Assiut University, from July 2018 to January 2024. Arm A (Conv-RT) included 100 patients, whereas arm B (Hypo-RT) had 50 patients. Results: There is no significant difference in the reduction of LVEF from baseline between the groups (p=0.080), with the majority of patients in both groups showing a reduction of less than 10%. Cardiac toxicity, whether asymptomatic or symptomatic, is also comparable between the two groups (p=0.203). Furthermore, all non-cardiac toxicities were acute and only grade I-II with the exception of lymphedema. There was lower incidence acute skin toxicity (10% versus 27%), fatigue (2% versus 7%), breast pain (4% versus 10%) with equal percentage of lymphedema cases (2%) in Hypo-RT compared with conventional RT, respectively. Conclusion: Hypo-RT administered concurrently with trastuzumab is safe and feasible with lower incidence of cardiac and skin toxicities compared with conventional RT in adjuvant breast cancer patients.so, longer follow-up period is needed to determine long term results. | ||||
| Keywords | ||||
| Breast cancer; HER2/neu positive; Trastuzumab; hypofractionated radiotherapy; conventional radiotherapy | ||||
|
Statistics Article View: 53 PDF Download: 31 |
||||
